Burden of Coronary Heart Disease Rehospitalizations Following Acute Myocardial Infarction in Older Adults

Cardiovascular Drugs and Therapy

Volumn 30, Issue 3, 2016, Pages 323-331

  Levitan, Emily B ^a   Muntner, Paul ^a   Chen, Ligong ^a   Deng, Luqin ^a   Kilgore, Meredith L ^a   Becker, David ^a   Glasser, Stephen P ^b   Safford, Monika M ^b,c   Howard, George ^a   Kilpatrick, Ryan ^d,e   Rosenson, Robert S ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d AMGEN INC   (United States)

^e Baxalta US   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary heart disease; Myocardial infarction; Recurrent hospitalization

Indexed keywords

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; GROUPS BY AGE; HEART FAILURE; HOSPITAL READMISSION; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; POISSON DISTRIBUTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY; HEART DISEASES; STATISTICS AND NUMERICAL DATA; UNITED STATES;

AGED; AGED, 80 AND OVER; FEMALE; HEART DISEASES; HUMANS; MALE; MEDICARE; PATIENT READMISSION; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84959084214     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-016-6653-6     Document Type: Article

References (19)

1. Rao SR, Schoenfeld DA. Survival methods. Circulation. 2007;115(1):109–13.
2. Nissen SE. Cardiovascular outcomes in randomized trials: should time to first event for “hard” end points remain the standard approach? J Am Coll Cardiol. 2009;54(25):2363–5.
3. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 Update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–73.
4. Stone NJ, Robinson J, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013.
5. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 suppl 2):S76–99.
6. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727–33.
7. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285–95.
8. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009;54(25):2358–62.
9. Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol. 2009;54(25):2353–7.
10. Kent ST, Safford MM, Zhao H, Levitan EB, Curtis JR, Kilpatrick RD, et al. Optimal use of available claims to identify a medicare population free of coronary heart disease. Am J Epidemiol. 2015;182(9):808–19.
11. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148(1):99–104.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706.
13. Davison AC, Hinkley DV. Bootstrap methods and their application. New York: Cambridge University Press; 1997.
14. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68(2):373–9.
15. Box-Steffensmeier JM, De Boef S. Repeated events survival models: the conditional frailty model. Stat Med. 2006;25(20):3518–33.
16. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014;16(1):33–40.
17. Borer JS, Bohm M, Ford I, Komajda M, Tavazzi L, Sendon JL, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813–20.
18. Anderson JL, Heidenreich PA, Barnett PG, Creager MA, Fonarow GC, Gibbons RJ, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129(22):2329–45.
19. Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circ: Cardiovasc Qual Outcomes. 2009;2(1):55–8.